Antagonism of LPA1 and LPA2 should attenuate pulmonary fibrosis to a greater extent than an irreversible LPA1 antagonist due to the ability of LPA2 to increase TGF-β levels. Here, LPAR2 is linked to pulmonary fibrosis.